A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Chinese Patients With Chronic Fibrosing ILDs With a Progressive Phenotype
Latest Information Update: 21 May 2024
At a glance
- Drugs Nintedanib (Primary)
- Indications Interstitial lung diseases; Pulmonary fibrosis
- Focus Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 15 May 2024 Status changed from active, no longer recruiting to completed.
- 30 Apr 2024 Planned End Date changed from 25 May 2024 to 7 May 2024.
- 30 Apr 2024 Planned primary completion date changed from 14 May 2024 to 30 Apr 2024.